Impact of duration of therapy on side effect profile of anti-HCV protocol: A retrospective cohort study from two tertiary health facilities in Pakistan by Saleem, Zikria et al.
Saleem et al 
Trop J Pharm Res, April 2017; 16(4): 931  
 
Tropical Journal of Pharmaceutical Research April 2017; 16 (4): 931-937 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v16i4.27 
Original Research Article 
 
 
Impact of duration of therapy on side effect profile of anti-
HCV protocol: A retrospective cohort study from two 
tertiary health facilities in Pakistan 
 
Zikria Saleem1*, Hamid Saeed1, Furqan K Hashmi1, Nouman Saleem1, Uzma 
Zafar1, Maham Farrukh1, Aina Salah1, Saliha Ilyas1, Sehrish Shafique1, Mahrukh 
Ahsan1, Zeeshan Danish2 and Muhammad Islam3 
1Department of Clinical Pharmacy, 2Department of Pharmaceutics, 3Department of Pharmaceutical Chemistry, Punjab 
University College of Pharmacy, University of the Punjab, Allama Iqbal Campus, 54000, Lahore, Pakistan 
 
*For correspondence: Email: zikria.pharmacy@pu.edu.pk; Tel: +92322-9801981; Fax: +92-42-99211624 
 
Received: 26 June 2016        Revised accepted: 9 March 2017 
 
Abstract 
Purpose: To evaluate the plausible risks and adverse effects related to the duration of therapy in 
hepatitis C (HCV) patients in Lahore, Pakistan. 
Method: A retrospective observational study involving 250 HCV patients who received combination 
therapy with ribavirin and interferon was conducted. The patients were segregated into two groups on 
the basis of duration of therapy (≤ 6 months and > 6 months). Adverse effect profiles of patients under 
treatment were collected using a pre-validated questionnaire and compared using Pearson’s Chi-
Square Test/Chi-Square Goodness-of-Fit tests and unpaired t-test.  
Results: Patients who underwent treatment for ≤ 6 months frequently encountered side-effects such as 
GIT disturbance (23.77 %) and joint pains (29.63 %). Additionally, diabetes mellitus (27.86 %) and 
frequent injections (74.59 %) were the most commonly observed co-morbid condition and disease risk, 
respectively. On the other hand, in patients who underwent therapy for > 6 months, skin disorders 
(30.46 %) and gastric acidity (10.15 %) were the most frequently observed side-effects with less 
frequent reporting on co-morbid conditions and disease risk factors. Moreover, there was a significant 
reduction in body weight (p = 0.03), serum bilirubin (p = 0.0005), albumin (p = 0.003) and triglycerides (p 
= 0.006) levels due to longer duration of treatment. 
Conclusion: The data suggest that treatment-related risks are higher among HCV patients on shorter 
treatment duration whereas adverse events subside in patients on longer duration of therapy (>6 
months). Changes in biochemical profile were also more evident in those receiving treatment for periods 
>6 months. 
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Hepatitis C is an infectious affliction that affects 
the functioning of hepatocyte owing to the 
hepatitis C virus (HCV), which can lead to life 
threatening pathological conditions such as 
cirrhosis, Hepato-cellular carcinoma and 
ultimately liver failure. HCV belongs to 
Flaviviridae family and is affecting over 170 
million people worldwide [1]. The exact 
mechanism of infection is still to be elucidated as 
HCV has different genotypes with varied 
responses towards antiviral therapy based on 
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HCV RNA load that is usually detected via 
polymerized chain reaction (PCR) [2]. Currently, 
no vaccine is available in the market for hepatitis 
C prophylaxis [3]. A standard combination 
therapy has been developed over a period of 
time for the treatment of HCV, constituting 
Interferon injection and oral ribavirin [4].  
 
The clinical objective of HCV treatment is to 
attain SVR for eradication of HCV-RNA with 6 
months of interferon (IFN) therapy [5]. However, 
interferon therapy causes numerous side-effects 
such as thyroid dysfunction, visual and auditory 
impairment, renal hypo-perfusion, cardiac 
problems, anemia and pulmonary fibrosis [6]. 
Although some of these side effects require 
reduction in dose while others require complete 
discontinuation of therapy [7].  
 
It is evident from the literature that interferon 
mono-therapy leads to side-effects as 
retinopathy, however the chances of such side-
effects become feeble when IFN is used in 
combination with anti-retroviral drugs as Ribavirin 
[8]. Some of the notable side effects include flu 
like symptoms, fever, chills, headache and 
myalgia along with leucopenia. Gastrointestinal 
related side-effects such as nausea, vomiting 
and diarrhea and even elevation of alanine 
aminotransferase levels are reported to be quite 
commonly encountered during the therapy [7]. 
Moreover, certain risks, such as alcohol intake 
and smoking can further aggravate the side 
effect profiles related to Interferon therapy and 
may compromise the clinical efficacy of these 
agents in HCV patients [9]. Higher doses of 
Interferon without checking the indicator levels in 
serum pose various adverse effects, which can 
be life threatening. Moreover, in the presence of 
risk factors, even the therapeutic dose of 
Interferon therapy can lead to many side effects 
requiring dose adjustment or discontinuation of 
therapy.  
 
The present study was conducted in two tertiary 
health care facilities to evaluate the anti-HCV 
therapy related side-effects, co-morbid conditions 
and risks in HCV patients of Pakistan with 






A retrospective observational study was 
designed to evaluate the risks and side effects 
related to therapy duration in 250 HCV 
diagnosed patients in Lahore. The patients were 
segregated into two arms, namely less than six 
months and greater than six months, based on 
the duration of treatment. 
 
Study population and setting 
 
A total of 250 patients were  selected as per 
defined inclusion and exclusion criteria of the 
study from out-patient departments of two 
teaching hospitals in Lahore, namely Mayo 




All HCV patients, irrespective of age, gender, 
ethnicity, education and socio-economic status, 
undergoing concurrent interferon and ribavirin 




All patients either on Interferon or Ribavirin 
monotherapy were excluded from the study. 
Similarly, patients with more than 2 co-





A 70-item instrument was designed to document 
patients’ demographics, medication history, 
disease history, co-morbidities, risk factors, 
therapy complications, side effects, and 
laboratory values retrospectively from the patient 
records. The questionnaire was validated by two 
researchers in the group by content and face 
validation methods. A team of trained data 
collectors facilitated the process of data 
collection from the two study settings.  The 
questionnaire consisted of 9 portions, such as 
demographics, family and medication history, 
disease history, co-morbidities associated with 
hepatitis C, risk factors, therapy complications, 




Data was analyzed using Statistical Package for 
Social Sciences (SPSS) version 21® (IBM 2013) 
and Pearson’s Chi-Square Test/Chi-Square 
Goodness-of-Fit was applied to compare 
different parameters of two groups based on the 
duration of therapy. This gives the OR (odd ratio) 




Approval for the study (no. ECCR/UCP/08/2015) 
was obtained from the Ethical Committee on 
Human Research, Punjab University College of 
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Pharmacy, University of the Punjab, Lahore. The 
study was also approved by Review Board on 
Clinical Research Ethics of Mayo and Jinnah 
Hospitals. All the procedures were in accordance 
with the principles of the Declaration of Helsinki 






Patient’s basic demographics are summarized in 
Table-1.Subjects comprised 57.2 % of women 
and 42.8 % men. About 52.4 % of patients 
ranged between 25 – 44 years of age (Table 1). 
Moreover, 91.2 % enrolled HCV patients were 
married out of which 52.4 % were housewives 
(Table 1). 
 
Risk factors and co-morbidities 
 
Potential risks and reported complications among 
the population in both the arms are summarized 
in Table 2. Notable risks with higher frequencies 
among patients with therapy duration of less or 
equal to six months include, injection (≤ 6 
months; 74.59 %, > 6 months; 69.76 %, p = 
0.032), diabetes (≤ 6 months; 27.86 %, > 6 
months; 17.18 %, p = 0.043) and liver related 
diseases (≤ 6 months; 14.75 %, > 6 months; 6.25 
%, p = 0.028) (Table 2). The risks and 
complications that were frequently higher in HCV 
patients with therapy duration of more than 6 
months include, family link (≤ 6 months; 14.75 %, 
> 6 months; 22.65 %, p = 0.041) and blood 
transfusion (≤ 6 months; 41.4 %, > 6 months; 
32.78 %, p = 0.027) (Table 2). 
Table 1: Patient’s basic demographics 
 
Parameter Duration of therapy  Total 
(n=250) ≤ 6 months 
(n=122) 
> 6 months  
(n=128) 
Age 
18-24 6 (4.91) 1(0.78) 7 (2.8) 
25-44 59 (48.36) 72 (56.25) 131 (52.4) 
45-64 55 (45.08) 51 (39.84) 106 (42.4) 
>65 2 (1.63) 4 (3.12) 6 (2.4) 
Gender 
Male 57 (53.27) 50 (39.06) 107 (42.8) 
Female 65 (53.27) 78 (60.93) 143 (57.2) 
Ethnic group 
Punjabi 104 (85.24) 111 (86.71) 215 (86) 
Pathan 9 (7.3) 5 (3.90) 14 (5.6) 
Sindhi 1 (0.81) 0 1 (0.4) 
Others 8 (6.55) 12 (9.37) 20 (8) 
Residential area 
Rural 56 (45.90) 55 (42.96) 111 (44.4) 
Urban 66 (54.09) 73 (57.03) 139 (55.6) 
Educational level 
Higher 7 (5.73) 2 (1.56) 9 (3.6) 
Secondary 17 (13.93) 15 (11.71) 32 (12.8) 
Middle 19 (15.57) 9 (7.03) 28 (11.2) 
Primary 46 (37.70) 29 (22.65) 75 (30) 
Illiterate 33 (27.04) 73 (57.03) 106 (42.4) 
Marital status 
Married 108 (88.5) 120 (93.75) 228 (91.2) 
Single 12 (9.83) 5 (4.09) 17 (6.8) 
Widow 2 (1.63) 3 (2.45) 5 (2) 
Occupation 
Housewife 58 (47.54) 73 (57.03) 131 (52.4) 
Labor 14 (11.47) 18 (14.06) 32 (12.8) 
Unemployed 12 (9.83) 7 (6.56) 19 (7.6) 
Others 38 (31.14) 30 (23.43) 68 (27.2) 
Source of medicine 
DHQ hospital 41 (33.60) 34 (26.56) 75 (30) 
Hospital 16 (13.11) 13 (10.15) 29 (11.6) 
Medical store 41 (33.60) 62 (48.43) 103 (41.2) 
Pharmacy 3 (2.45) 2 (1.56) 5 (2) 
Others 21 (17.21) 17 (13.28) 38 (15.2) 
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Side effect profiles among HCV patients on 
anti-HCV combination therapy 
 
Table 3 illustrates the side effect profiles and 
clinical presentation of enrolled HCV patients. 
Noteworthy clinical features among HCV patients 
in both the arms include, respiratory tract 
infection (≤ 6 months; 30.32 %, > 6 months; 53.9 
%, p = 0.0005), skin disorder (≤ 6 months; 19.67 
%, > 6months; 30.46 %, p = 0.049) and cough (≤ 
6 months; 4.09 %, > 6 months; 0.78 %, p = 
0.047) (Table 3). Moreover, the most frequently 
reported side effects were bleeding disorders (≤ 
6 months; 52.45 %, > 6 months; 52.34 %), 
vomiting (≤ 6 months; 38.52 %, > 6 months; 
42.18 %), joint disorders (≤ 6 months; 29.63 %, > 
6 months; 23.75 %, p = 0.029), headache (≤ 6 
months; 25.40 %, > 6 months; 33.59 %) and 




Table 2: Risk factors and co-morbidities among the enrolled patients 
 






≤ 6 months 
(n=122) 
> 6 months 
(n=128) 
Smoking 34 (27.86) 32 (25) 66 (26.4) 0.84 
Family history 18 (14.75) 29 (22.65) 47 (18.8) 0.041* 
Pregnancy 5 (4.09) 1 (0.78) 6 (2.4) 0.039* 
Dengue fever 15 (12.29) 15 (11.71) 30 (12) 0.97 
Blood transfusion 40 (32.78) 53 (41.40) 93 (37.2) 0.027* 
Hemodialysis 0 (0) 2(1.56) 2 (0.8) 0.071 
Injection 91 (74.59) 87 (67.96) 178 (71.2) 0.032* 
Contact with infected person 23 (18.85) 22 (17.18) 45 (18) 0.199 
Shaving outside 26 (21.31) 23 (17.96) 49 (19.6) 0.062 
Diabetes mellitus 34 (27.86) 22 (17.18) 56 (22.4) 0.043* 
Hypertension 27 (22.13) 30 (23.43) 57 (22.8) 0.806 
Other liver diseases 18 (14.75) 8 (6.25) 26 (10.4) 0.028* 
†Pearson’s Chi-Square Test/Chi-Square Goodness-of-Fit; *significant p value < 0.05; ** highly significant, p < 
0.005; ns = non-significant 
 
Table 3: Clinical presentation and side-effect profiles  
 






≤ 6 months 
(n=122) 
> 6 months  
(n=128) 
Abdominal pain 58 (47.54) 72 (56.25) 130 (51.58) 0.168 
Fever 96 (78.68) 97 (75.78) 193 (77.2) 0.584 
Genitourinary symptoms 4 (3.27) 8 (6.25) 12 (4.8) 0.272 
Muscular pain 61 (50) 70 (54.68) 131 (52.4) 0.458 
Respiratory tract infection 37 (30.32) 69 (53.90) 106 (42.4) 0.0005** 
Hepatic  encephalopathy 46 (37.70) 38 (29.68) 84 (33.6) 0.18 
Ascites 15 (12.29) 10 (7.8) 25 (10) 0.238 
Cough  5 (4.09) 1 (0.78) 6 (2.4) 0.047* 
Side Effects  
Vomiting 47 (38.52) 54 (42.18) 101 (40.4) 0.24 
Eye disorder 34 (27.86) 26 (20.31) 60 (24) 0.149 
Skin disorders 24 (19.67) 39 (30.46) 63 (25.2) 0.049* 
Joint disorder 36 (29.63) 31 (23.75) 67 (26.8) 0.029* 
Headache 31 (25.40) 43 (33.59) 74 (29.6) 0.06 
Insomnia 24 (19.67) 33 (25.78) 57 (22.8) 0.06 
Irritability 13 (10.65) 4 (3.12) 17 (6.8) 0.06 
Acidity 2 (1.63) 13 (10.15) 15 (6) 0.002** 
Loss of appetite 17 (13.93) 17 (13.28) 34 (13.6) 0.849 
GIT disturbances  29 (23.77) 14 (10.93) 43 (17.2) 0.002** 
Bleeding disorder 64 (52.45) 67 (52.34) 131 (52.4) 0.642 
Minor bleeding 47 (38.52) 54 (42.18) 101 (40.4) 0.643 
Major bleeding 17 (13.92) 15 (11.71) 31 (12.8) 0.493 
Nasal bleeding 3 (2.45) 4 (3.12) 7 (2.8) 0.949 
Rectal bleeding 8 (6.55) 7 (5.46) 15 (6) 0.549 
† Pearson’s Chi-Square Test/Chi-Square Goodness-of-Fit; * significant, p < 0.05; ** highly significant, p < 0.005; 
ns = non-significant 
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Table 4: Laboratory findings for the patients 
 






≤ 6 months 
(n=122) 
> 6 months  
(n=128) 
Weight (kg) 66.35 ± 19.24 61.08 ± 16.35 5.27399 0.03* 
Serum ALT (IU/L) 60.48 ± 30.31 61.14 ± 37.07 -0.66715 0.159 
Serum AST (IU/L) 42.08 ± 33.01 45.72 ± 33 -3.63369 0.24 
Bilirubin (mg/dL) 1.53 ± 1.21 0.92 ± 0.85 0.60457 0.0005** 
Alkaline 
phosphatase (IU/L) 
236.87 ± 103.15 208.4 ± 58.15 28.47562 0.135 
HB level (g/dL) 11.24 ± 1.99 10.98 ± 2.18 0.26444 0.592 
Albumin (g/dL) 6.16 ± 10.14 3.47 ± 0.82 2.68501 0.003** 
Prothrombin Time 
(min) 
9.27 ± 2.95 10.07 ± 3.38 -0.80272 0.359 
Platelets (103/uL) 206.820 ± 107.244 211.170 ±117.284 -4.3512 0.147 
Leukocytes 
(no./uL) 
13482 ± 87798.74 5528.5 ± 16110.37 7953.2843 0.433 
Cholesterol 
(mg/dL) 
138.11 ± 26.19 136.21 ± 14.27 1.89881 0.304 
Triglycerides 
(mg/dL) 
147.53 ± 43.79 121.65 ± 29.52 25.87247 0.006* 
HCV RNA (IU/ml) 90735 ± 123207 73939 ± 185206 16796.874 0.115 
† Independent sample t-test ¥≤ 6 months> 6 months; * significant, p < 0.05; **highly significant, p 




Clinical lab values of the patients enrolled in both 
the arms are summarized in (Table 4). As shown 
in Table 4. No significant differences were 
observed in both the arms for majority of the lab 
values except for bilirubin (≤ 6 months; 1.53 ± 
1.21, > 6 months; 0.92 ± 0.85, p = 0.0005), 
albumin (≤ 6 months; 6.16 ± 10.14, > 6 months; 
3.47 ± 0.82 p = 0.003) and triglycerides (≤ 6 
months; 147.53 ± 43.79, > 6 months; 121.65 ± 




The incidences of HCV are seen to be more in 
urban societies and in particular in illiterate 
people due to lack of knowledge about the 
associated risks with re-use of needles and other 
such articles [14]. Studies have shown that 
majority of the side effects associated with 
Interferon therapy subside on therapy withdrawal 
and less likely to recur on initiating the therapy 
with a lower dose [15]. Combination therapy of 
Interferon and Ribavirin is also associated with 
numerous predictable side-effects. The 
unpredictable side effects were usually caused 
due to age, gender, duration of therapy and co-
morbidities [16]. Moreover, the occurrence of 
some of the side-effects has been attributed to 
long term therapy with Interferon and Ribavirin, 
requiring either dose reduction or discontinuation 
of therapy. 
 
Literature evidences suggest that duration of 
anti-HCV therapy coupled with higher Interferon 
doses can cause various side effects, most of 
them unpredictable [17]. Our data suggested that 
some of the side effects such as headache, 
insomnia,  gastric acidity, vomiting and bleeding 
were more pronounced in patients with anti-HCV 
treatment duration for more than six months, 
whereas the other group showed fewer. 
However, the side-effects that subsided with the 
passage of time were joint pains, optical disorder 
(retinopathy), muscle problems (muscular pain), 
autoimmune disorders (arthritis), CNS problems 
(headache, insomnia), abdominal pain, 
respiratory problems (difficult breathing) and 
hematological problems (anemia, bleeding).  
 
Furthermore, our findings are in agreement with 
previous reports [7] that have suggested that 
some of the side-effects like anemia, fever, 
headache, respiratory problems (difficulty in 
breathing), muscular problems and skin 
problems might exacerbate after 6 months of 
therapy, which leads to  dose reduction or 
therapy withdrawal. Our data further suggested 
that anemia worsened with increasing therapy 
duration of more than 6 months, consistent with 
previous reports anemia being most common 
side-effect of Interferon and Ribavirin therapy 
possibly due to direct toxic effects of ribavirin on 
RBCs promoting hemolysis [18]. Studies have 
also shown that Interferon therapy in HCV 
patients with hypertension can induce or 
aggravate retinopathy possibly due to narrowing 
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of arteries affecting retinal microcirculation [19]. 
Interferon therapy can also induce skin, CVS and 
musculoskeletal side effects [20] and can 
precipitate or perpetrate pathological events 
favoring autoimmune diseases [21]. Along with 
side-effects, numerous therapy and patient-
related risks can compromise the clinical efficacy 
of interferon therapy and further aggravate the 
disease condition. The risk factors that are 
believed to complicate interferon therapy include 
smoking, alcohol, blood transfusion and use of 
non-sterilized personal hygiene products as razor 
blades for shaving.  
 
Our data also suggested that effectiveness of 
Interferon therapy was reduced in smokers and 
in individuals with co-morbidities such as 
diabetes mellitus and hypertension. Similar 
results have been reported previously, 
suggesting that these risk factors can prolong 
therapy duration which may result in serious side 
effects [22]. Smoking increases the chances of 
fibrosis and damage to the liver in patients with 
chronic hepatitis C [23]. Another study suggested 
that Type 2 diabetes is more common in patients 
with HCV infection [24]. Therefore, all these side 
effects and risk factors not only resulted in 
reduced therapy responses but also favored 
prolonged treatment further complicating disease 




The present study has some limitations. We were 
unable to ensure random sampling; no standard 
criteria was used for documenting side effect 
profiles; and we were unable to associate the 
impact of disease duration with therapy duration 
and reported risks and complications. Moreover, 
the study was carried out in only two healthcare 





The combination of interferon and ribavirin for the 
treatment of hepatitis C was associated with 
several side effects which could be aggravated 
by concomitant exposure to risk factors, such as 
smoking, blood transfusion, use of non-sterile 
tools for surgical and medical procedures. 
Besides concomitant disease risks, diabetes and 
hypertension might favor therapy-related side 
effects and could hinder optimal therapeutic 
response. Seemingly, the presence of either 
disease risks or co-morbidities may further 
exacerbate the side-effects, possibly by 
prolonging therapy duration and compromising 
clinical efficacy of anti-HCV. The data suggest 
that treatment-related risks are higher in the first 
group of patients whereas adverse events are 
lower in patients on longer duration of therapy 
(>6 months). However, Changes in biochemical 
profiles of patients were also more pronounced in 
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